Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. (Q46019776)
Jump to navigation
Jump to search
scientific article published in September 2008
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. |
scientific article published in September 2008 |
Statements
1 reference
Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. (English)
1 reference
Mark C Genovese
1 reference
Jeffrey L Kaine
1 reference
Mitchell B Lowenstein
1 reference
José Del Giudice
1 reference
Andrew Baldassare
1 reference
Joy Schechtman
1 reference
Edward Fudman
1 reference
Michael Kohen
1 reference
Sheila Gujrathi
1 reference
Robert G Trapp
1 reference
Nadera J Sweiss
1 reference
Greg Spaniolo
1 reference
Wolfgang Dummer
1 reference
ACTION Study Group
1 reference
1 September 2008
1 reference
1 reference
58
1 reference
2652-2661
1 reference
9
1 reference
1 reference
Identifiers
1 reference
1 reference